JP2020519298A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519298A5 JP2020519298A5 JP2019563082A JP2019563082A JP2020519298A5 JP 2020519298 A5 JP2020519298 A5 JP 2020519298A5 JP 2019563082 A JP2019563082 A JP 2019563082A JP 2019563082 A JP2019563082 A JP 2019563082A JP 2020519298 A5 JP2020519298 A5 JP 2020519298A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- construct
- domain
- seq
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 15
- 102000038129 antigens Human genes 0.000 claims 15
- 108091007172 antigens Proteins 0.000 claims 15
- 230000003834 intracellular Effects 0.000 claims 6
- 230000011664 signaling Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 108090001126 FURIN Proteins 0.000 claims 2
- 102000004961 Furin Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 102100005826 CD19 Human genes 0.000 claims 1
- 101700087100 CD19 Proteins 0.000 claims 1
- 102100000189 CD22 Human genes 0.000 claims 1
- 101700020617 CD22 Proteins 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
Claims (17)
- (a)切断可能なドメイン;
(b)第一の抗原結合ドメイン、
第一の膜貫通ドメイン、及び
第一の細胞内T細胞シグナル伝達ドメイン
を含む第一のCAR;並びに
(c)第二の抗原結合ドメイン、
第二の膜貫通ドメイン、及び
第二の細胞内T細胞シグナル伝達ドメイン
を含む第二のCAR;
を含む、キメラ抗原受容体(CAR)アミノ酸コンストラクトであって、
第一及び第二のCARが、切断可能なドメインを介して連結され、
(i)第一の抗原結合ドメインが、配列番号4、6、及び8の重鎖可変領域CDR配列、並びに配列番号12、14、及び16の軽鎖可変領域CDR配列を含み、且つ
第一のCARがコンストラクトから切断される場合、第一の抗原結合ドメインはCD22に対する抗原特異性を有するか;または、
(ii)第一の抗原結合ドメインが、配列番号24、26、及び28の軽鎖可変領域CDR配列、並びに配列番号32、34、及び36の重鎖可変領域CDR配列を含み、且つ
第一のCARがコンストラクトから切断される場合、第一の抗原結合ドメインはCD19に対する抗原特異性を有する、コンストラクト。 - 第一の抗原結合ドメインが、配列番号4、6、及び8の重鎖可変領域CDR配列、並びに配列番号12、14、及び16の軽鎖可変領域CDR配列を含む、請求項1に記載のCARコンストラクト。
- 第一の抗原結合ドメインが、配列番号24、26、及び28の軽鎖可変領域CDR配列、並びに配列番号32、34、及び36の重鎖可変領域CDR配列のアミノ酸配列を含む、請求項1に記載のCARコンストラクト。
- 第二の抗原結合ドメインが、配列番号24、26、及び28の軽鎖可変領域CDR配列、並びに配列番号32、34、及び36の重鎖可変領域CDR配列を含む、請求項2に記載のCARコンストラクト。
- 切断可能なドメインが2A又はフューリンである、請求項1〜4のいずれか1項に記載のCARコンストラクト。
- 切断可能なドメインが2A及びフューリンである、請求項1〜4のいずれか1項に記載のCARコンストラクト。
- CARコンストラクトが、それぞれ第一及び第二のCARである、ちょうど2つのCARを含む、請求項1〜6のいずれか1項に記載のCARコンストラクト。
- CARが、配列番号48、49、50、51、若しくは52のアミノ酸配列、又は配列番号63〜70のいずれか1と90%以上の配列同一性を有するアミノ酸配列を含む、請求項1に記載のCARコンストラクト。
- CARが、配列番号49のアミノ酸配列を含む、請求項1に記載のCAR。
- (a)2以上の切断可能なドメイン;
(b)第一の抗原結合ドメイン、
第一の膜貫通ドメイン、及び
第一の細胞内T細胞シグナル伝達ドメイン
を含む第一のCAR;並びに
(c)第二の抗原結合ドメイン、
第二の膜貫通ドメイン、及び
第二の細胞内T細胞シグナル伝達ドメイン
を含む第二のCAR;
を含む、キメラ抗原受容体(CAR)アミノ酸コンストラクトであって、
第一及び第二のCARが、2以上の切断可能なドメインを介して連結される、コンストラクト。 - ちょうど2つの切断可能なドメインが存在する、請求項10のCARコンストラクト。
- 請求項1〜11のいずれか1項のCARアミノ酸コンストラクトをコードするヌクレオチド配列を含む、核酸。
- 請求項12の核酸を含む組換え発現ベクターを含む、単離された宿主細胞。
- 請求項1〜11のいずれか1項のCARコンストラクト、請求項12の核酸、請求項13の宿主細胞又はその細胞集団と、医薬的に許容される担体とを含む、医薬組成物。
- 哺乳動物における、がんの治療のための医薬組成物であって、請求項1〜11のいずれか1項のCARコンストラクト、請求項12の核酸、請求項13の宿主細胞若しくはその細胞集団、又は請求項14の医薬組成物を有効成分として含む、医薬組成物。
- 前記がんが、血液悪性腫瘍である、請求項15の医薬組成物。
- キメラ抗原受容体(CAR)アミノ酸コンストラクトの作製方法であって、
(a)第一の抗原結合ドメイン、
第一の膜貫通ドメイン、及び
第一の細胞内T細胞シグナル伝達ドメイン
を含む第一のCAR;並びに
(b)第二の抗原結合ドメイン、
第二の膜貫通ドメイン、及び
第二の細胞内T細胞シグナル伝達ドメイン
を含む第二のCAR
の間に2以上の切断可能なドメインを設計し、第一及び第二のCARが該2以上の切断可能なドメインを介して連結されること;そして
第一のCAR、2以上の切断可能なドメイン、及び第二のCARを、N末端からC末端までに含む配列を、プラスミドにクローニングすること
を含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762506268P | 2017-05-15 | 2017-05-15 | |
US62/506,268 | 2017-05-15 | ||
PCT/US2018/032809 WO2018213337A1 (en) | 2017-05-15 | 2018-05-15 | Bicistronic chimeric antigen receptors and their uses |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020519298A JP2020519298A (ja) | 2020-07-02 |
JP2020519298A5 true JP2020519298A5 (ja) | 2021-07-26 |
Family
ID=62685125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019563082A Pending JP2020519298A (ja) | 2017-05-15 | 2018-05-15 | バイシストロン性キメラ抗原受容体及びそれらの使用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11980640B2 (ja) |
EP (1) | EP3625261A1 (ja) |
JP (1) | JP2020519298A (ja) |
KR (1) | KR20200005655A (ja) |
CN (1) | CN110650975B (ja) |
AU (1) | AU2018269194A1 (ja) |
CA (1) | CA3062433A1 (ja) |
WO (1) | WO2018213337A1 (ja) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201609960QA (en) * | 2014-06-02 | 2016-12-29 | Us Health | Chimeric antigen receptors targeting cd-19 |
WO2016149578A1 (en) | 2015-03-19 | 2016-09-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-cd22-anti-cd19 chimeric antigen receptors |
CA3062433A1 (en) | 2017-05-15 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
IT201800003464A1 (it) * | 2018-03-13 | 2019-09-13 | Ospedale Pediatrico Bambino Gesu | Cellule T CAR-CD30 per il trattamento di tumori CD30+ |
WO2020069409A1 (en) * | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
KR20210102941A (ko) | 2018-12-12 | 2021-08-20 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
CN113490510A (zh) | 2019-01-08 | 2021-10-08 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗实体瘤的靶向间皮素的跨物种单结构域抗体 |
AU2020212534A1 (en) | 2019-01-22 | 2021-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
CN113874391A (zh) * | 2019-02-20 | 2021-12-31 | 希望之城公司 | 靶向baff-r/cd19的嵌合抗原受体修饰的t细胞及其用途 |
CA3136618A1 (en) * | 2019-04-10 | 2020-10-15 | Elevatebio Technologies, Inc. | Flt3-specific chimeric antigen receptors and methods of using the same |
TW202110873A (zh) | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | 嵌合受體及其使用方法 |
GB201906283D0 (en) * | 2019-05-03 | 2019-06-19 | Moredun Res Institute | Vector |
EP3966236A4 (en) * | 2019-05-07 | 2023-05-10 | The Board of Trustees of the Leland Stanford Junior University | IMPROVEMENT OF POLYPEPTIDES AND CHIMERA ANTIGEN RECEPTORS ACROSS HINGE DOMAINS |
CA3142159A1 (en) * | 2019-05-31 | 2020-12-03 | City Of Hope | Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies |
CN112390891B (zh) * | 2019-08-14 | 2022-06-03 | 苏州方德门达新药开发有限公司 | 嵌合抗原受体及其构建方法和应用 |
EP4031250A1 (en) | 2019-10-22 | 2022-07-27 | The United States of America, as represented by the Secretary, Department of Health and Human Services | High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors |
CN115427439A (zh) * | 2019-10-30 | 2022-12-02 | 德克萨斯A&M大学系统 | 用于双靶标嵌合抗原受体t细胞疗法的蛋白酶开关 |
WO2021108613A1 (en) * | 2019-11-26 | 2021-06-03 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
WO2021168000A1 (en) * | 2020-02-17 | 2021-08-26 | University Of Virginia Patent Foundation | CAR T CELLS TARGETING THE INTEGRIN ALPHAv BETA3 EXHIBIT ROBUST ANTI-TUMOR RESPONSES AGAINST GLIOMAS AND OTHER SOLID TUMOR MALIGNANCIES |
CN113493517B (zh) * | 2020-04-02 | 2023-05-02 | 重庆精准生物技术有限公司 | 双特异性单链抗体及其构建的嵌合抗原受体和应用 |
CN113493516A (zh) * | 2020-04-02 | 2021-10-12 | 重庆精准生物技术有限公司 | 靶向双特异性位点的嵌合抗原受体及其应用 |
CN111632135A (zh) * | 2020-05-09 | 2020-09-08 | 深圳宾德生物技术有限公司 | 靶向nkg2d的嵌合抗原受体t细胞在治疗前列腺癌中的应用、治疗前列腺癌的药物 |
CA3171101A1 (en) * | 2020-06-22 | 2021-12-30 | Dina SCHNEIDER | Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy |
US20230391852A1 (en) | 2020-10-26 | 2023-12-07 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
CA3202218A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
EP4271404A2 (en) | 2020-12-31 | 2023-11-08 | Sana Biotechnology, Inc. | Methods and compositions for modulating car-t activity |
EP4274901A1 (en) | 2021-01-11 | 2023-11-15 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
CN112961245B (zh) * | 2021-02-24 | 2023-07-25 | 重庆精准生物技术有限公司 | 一种靶向cd96的双特异性抗体及其制备方法和用途 |
US20240218055A1 (en) | 2021-04-29 | 2024-07-04 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
BR112023024231A2 (pt) | 2021-05-19 | 2024-01-30 | Sana Biotechnology Inc | Células t primárias rhd negativas hipoimunogênicas |
EP4347797A1 (en) | 2021-05-27 | 2024-04-10 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
US20240270851A1 (en) | 2021-06-09 | 2024-08-15 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Cross species single domain antibodies targeting pd-l1 for treating solid tumors |
AU2022309875A1 (en) | 2021-07-14 | 2024-01-25 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
TW202321457A (zh) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | 靶向cd4之病毒載體之用途 |
WO2023019203A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Inducible systems for altering gene expression in hypoimmunogenic cells |
EP4384193A2 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
WO2023019227A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
EP4384189A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
WO2023076881A1 (en) | 2021-10-26 | 2023-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein |
KR20240099402A (ko) | 2021-11-09 | 2024-06-28 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 글리피칸-3(gpc3)을 표적으로 하는 igg4 힌지-포함 키메라 항원 수용체 및 이의 용도 |
TW202342757A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科附著醣蛋白 |
WO2023115039A2 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
CN114478803B (zh) * | 2022-02-11 | 2023-09-26 | 北京大学深圳研究生院 | 一种新型双特异性嵌合抗原受体的构建及其应用 |
WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
WO2023158986A1 (en) | 2022-02-15 | 2023-08-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd28 hinge and transmembrane containing chimeric antigen receptors targeting gpc2 and use thereof |
IL315000A (en) | 2022-02-17 | 2024-10-01 | Sana Biotechnology Inc | Transgenic CD47 proteins and their uses |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
WO2024050399A1 (en) | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
WO2024097311A2 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Hypoimmunogenic mail cells, methods of making and methods of using same |
WO2024098038A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Polynucleotide construct and related viral vectors and methods |
WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
WO2024220560A1 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
WO2024220574A1 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
WO2024220598A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Lentiviral vectors with two or more genomes |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8591889B2 (en) | 2008-04-04 | 2013-11-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human monoclonal antibodies specific for CD22 |
EP3214091B1 (en) | 2010-12-09 | 2018-10-03 | The Trustees of The University of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
CN109485730A (zh) | 2011-10-20 | 2019-03-19 | 美国卫生和人力服务部 | 抗cd22嵌合抗原受体 |
EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
AU2013335180B2 (en) | 2012-10-24 | 2018-07-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | M971 chimeric antigen receptors |
MX2016008076A (es) * | 2013-12-19 | 2016-08-12 | Novartis Ag | Receptores quimericos de antigeno de mesotelina humana y uso de los mismos. |
LT3149031T (lt) * | 2014-05-29 | 2020-05-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T ląstelių receptoriai prieš žmogaus papilomos virusą 16 e7 |
SG11201609960QA (en) | 2014-06-02 | 2016-12-29 | Us Health | Chimeric antigen receptors targeting cd-19 |
AU2015292755B2 (en) * | 2014-07-21 | 2020-11-12 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
RU2022102250A (ru) * | 2014-12-24 | 2022-03-23 | Отолус Лимитед | Клетка |
WO2016149578A1 (en) * | 2015-03-19 | 2016-09-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-cd22-anti-cd19 chimeric antigen receptors |
IL303972A (en) | 2015-04-08 | 2023-08-01 | Novartis Ag | CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell |
SG10201913682QA (en) | 2015-06-25 | 2020-03-30 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
CN105647873A (zh) * | 2016-03-14 | 2016-06-08 | 紫程瑞生会(北京)生物技术发展有限公司 | 一种双特异性嵌合抗原受体基因修饰的自然杀伤细胞的制备方法及其试剂盒 |
CA3062433A1 (en) | 2017-05-15 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
US10822412B2 (en) | 2018-09-26 | 2020-11-03 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy |
-
2018
- 2018-05-15 CA CA3062433A patent/CA3062433A1/en active Pending
- 2018-05-15 AU AU2018269194A patent/AU2018269194A1/en active Pending
- 2018-05-15 US US16/613,187 patent/US11980640B2/en active Active
- 2018-05-15 CN CN201880032676.5A patent/CN110650975B/zh active Active
- 2018-05-15 KR KR1020197036903A patent/KR20200005655A/ko not_active Application Discontinuation
- 2018-05-15 JP JP2019563082A patent/JP2020519298A/ja active Pending
- 2018-05-15 EP EP18733012.1A patent/EP3625261A1/en active Pending
- 2018-05-15 WO PCT/US2018/032809 patent/WO2018213337A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020519298A5 (ja) | ||
JP2019514361A5 (ja) | ||
JP2022109953A5 (ja) | ||
ES2773527T3 (es) | Receptor quimérico para antígeno | |
JP2013509879A5 (ja) | ||
JP2016502512A5 (ja) | ||
JP2018531014A5 (ja) | ||
JP2019535262A5 (ja) | ||
JP2019521643A5 (ja) | ||
JP2018529380A5 (ja) | ||
RU2015122484A (ru) | Агенты для лечения экспрессирующих клаудин раковых заболеваний | |
CA2561826A1 (en) | Linear single chain recombinant anti-cea/cd3/cd28 trispecific antibody | |
JP2018537087A5 (ja) | ||
JP2017537627A5 (ja) | ||
JP2013502226A5 (ja) | ||
JP2020500015A5 (ja) | ||
JP2018523484A (ja) | 細胞 | |
JP2010273685A5 (ja) | ||
JP2018536431A5 (ja) | ||
JP2019506166A5 (ja) | ||
JP2012025766A5 (ja) | ||
JP2012025737A5 (ja) | ||
JP2018501794A5 (ja) | ||
JP2008504012A5 (ja) | ||
JP2018505139A5 (ja) |